Ben Richardson, CEO at SulNOx, confident they can cost-effectively decarbonise commercial shipping. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksLloyds Regulatory News (LLOY)

Share Price Information for Lloyds (LLOY)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 51.88
Bid: 51.86
Ask: 51.88
Change: -0.42 (-0.80%)
Spread: 0.02 (0.039%)
Open: 52.68
High: 52.82
Low: 51.72
Prev. Close: 52.30
LLOY Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Publication of Suppl.Prospcts

27 Apr 2017 17:28

RNS Number : 6162D
Lloyds Banking Group PLC
27 April 2017
 

27 April 2017

 

Publication of Supplementary Prospectus

The following Supplementary Prospectus has been approved by the UK Listing Authority and is available for viewing:

Supplementary Prospectus dated 27 April 2017 (the "Supplementary Prospectus") relating to the £25,000,000,000 Euro Medium Term Note Programme of Lloyds Banking Group plc.

The Supplementary Prospectus should be read and construed in conjunction with the base prospectus dated 30 March 2017 (the "Base Prospectus").

To view the Supplementary Prospectus, please paste the following URL into the address bar of your browser:

http://www.rns-pdf.londonstockexchange.com/rns/6162D_-2017-4-27.pdf

The Supplementary Prospectus has been submitted to the National Storage Mechanism and will shortly be available for inspection at: www.Hemscott.com/nsm.do.

For further information, please contact:

Investor Relations:

 

Douglas RadcliffeGroup Investor Relations Director 

Tel: +44 20 7356 1571

Email: douglas.radcliffe@finance.lloydsbanking.com

 

Corporate Affairs:

 

Matt Smith

Head of Corporate Media

Tel: +44 20 7356 3522

E-mail: matt.smith@lloydsbanking.com

 

Lloyds Banking Group plcRegistered OfficeThe MoundEdinburghEH1 1YZ

 

DISCLAIMER - INTENDED ADDRESSEES

Please note that the information contained in this announcement and the Supplementary Prospectus may be addressed to and/or targeted at persons who are residents of particular countries (specified in the Base Prospectus) only and is not intended for use and should not be relied upon by any person outside these countries and/or to whom this announcement and the Supplementary Prospectus are not addressed. Prior to relying on the information contained in this announcement and the Supplementary Prospectus, you must ascertain from the Base Prospectus whether or not you are one of the intended addressees of the information contained in this announcement and the Supplementary Prospectus.

In particular, this announcement and the Supplementary Prospectus do not constitute an offer or invitation to subscribe for, or purchase, securities in the United States or in any other jurisdiction where such an offer or invitation would be unlawful. This announcement and the Supplementary Prospectus are not for distribution in the United States. The securities described herein have not been, and will not be, registered under the U.S. Securities Act of 1933, as amended (the "Securities Act"), or under any relevant securities laws of any state of the United States of America and are subject to U.S. tax law requirements. Subject to certain exceptions, the securities may not be offered or sold within the United States or to, or for the account or benefit of, U.S. persons or to persons within the United States of America, as such terms are defined in Regulation S under the Securities Act. There will be no public offering of the securities in the United States. For a description of the restrictions on offers and sales of the securities described herein, please refer to the Supplementary Prospectus and Base Prospectus.

Your right to access this service is conditional upon complying with the above requirement.

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
PSPEAKLXAASXEFF
Date   Source Headline
21st Mar 20235:40 pmRNSTransaction in Own Shares
20th Mar 20235:26 pmRNSTransaction in Own Shares
17th Mar 20235:28 pmRNSTransaction in Own Shares
16th Mar 20235:47 pmRNSTransaction in Own Shares
15th Mar 20235:33 pmRNSTransaction in Own Shares
14th Mar 20235:20 pmRNSTransaction in Own Shares
13th Mar 20235:29 pmRNSTransaction in Own Shares
10th Mar 20235:58 pmRNSTransaction in Own Shares
10th Mar 20234:07 pmRNSDirector/PDMR Shareholding
9th Mar 20235:43 pmRNSTransaction in Own Shares
8th Mar 20236:06 pmRNSTransaction in Own Shares
8th Mar 20232:26 pmRNSDirector/PDMR Shareholding
7th Mar 20235:39 pmRNSTransaction in Own Shares
7th Mar 20233:08 pmRNS2022 Form 20F Filed
7th Mar 202310:37 amRNS2022 Annual Report and Accounts
7th Mar 202310:37 amRNS2022 Annual Report and Accounts
6th Mar 20235:52 pmRNSTransaction in Own Shares
3rd Mar 20235:41 pmRNSTransaction in Own Shares
2nd Mar 20235:37 pmRNSTransaction in Own Shares
2nd Mar 202312:04 pmRNSPublication of Final Terms
1st Mar 20235:26 pmRNSTransaction in Own Shares
28th Feb 20235:41 pmRNSTransaction in Own Shares
28th Feb 20233:37 pmRNSTotal Voting Rights
27th Feb 20235:26 pmRNSTransaction in Own Shares
27th Feb 20232:00 pmRNSDirector/PDMR Shareholding
24th Feb 20235:46 pmRNSTransaction in Own Shares
24th Feb 20235:03 pmRNS2022 Form 20F Filed
23rd Feb 20236:07 pmRNSTransaction in Own Shares
23rd Feb 20237:00 amRNSShare Buyback Programme Commences
22nd Feb 202311:38 amRNSPublication of Suppl.Prospcts
22nd Feb 20237:00 amRNS2022 Annual Report and Accounts
22nd Feb 20237:00 amRNS2022 Full Year Results
10th Feb 20235:00 pmRNSDirector/PDMR Shareholding
31st Jan 20234:57 pmRNSTotal Voting Rights
11th Jan 20232:36 pmRNSPublication of Final Terms
11th Jan 20232:15 pmRNSDirector/PDMR Shareholding
3rd Jan 202310:00 amRNSBlock listing Interim Review
3rd Jan 20237:00 amRNSTotal Voting Rights
16th Dec 20224:36 pmRNSDirector/PDMR Shareholding
12th Dec 20224:09 pmRNSDirector/PDMR Shareholding
7th Dec 20222:00 pmRNSBlock Listing of Shares
1st Dec 20229:57 amRNSDirector/PDMR Shareholding
30th Nov 20223:31 pmRNSTotal Voting Rights
16th Nov 20224:30 pmRNSDirector/PDMR Shareholding
10th Nov 20223:30 pmRNSDirector/PDMR Shareholding
1st Nov 20229:43 amRNSDirector Declaration
31st Oct 20222:18 pmRNSTotal Voting Rights
27th Oct 202212:07 pmRNSPublication of Supplementary Prospectus
27th Oct 202212:01 pmRNS2022 Q3 Interim Management Statement
27th Oct 20227:00 amRNS2022 Q3 Interim Management Statement

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.